Postneoadjuvant Trastuzumab Deruxtecan Results in Higher Likelihood of iDFS Among Patients with HER2-positive EBC with Residual Invasive Disease After Neoadjuvant Treatment By Ogkologos - December 12, 2025 51 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the interim analysis of the DESTINY-Breast05 study Source RELATED ARTICLESMORE FROM AUTHOR The Legacy of the ESMO Patient Engagement Summit 2025: Advancing Rights of Patients with Cancer via Cross-Border Best Practices and Collaboration Sustained PFS Benefit of Imlunestrant Over SoC in Patients with ESR1-mutated Advanced Breast Cancer ESMO Welcomes Launch of Health Package Introducing EU Measures That Can Boost Innovation in Oncology and Help Prevent New Cancer Cases MOST POPULAR Long-Term Outcomes Suggest a Sustained Clinical Benefit to Metastasis-Directed Treatment Over... August 31, 2022 Adjuvant Therapy with Oxaliplatin Added to Fluoropyrimidine Improves Survival in Patients... January 15, 2021 Incidence of Colorectal, Breast, Kidney, Pancreatic, and Uterine Cancers is Increasing... May 18, 2022 FDA Approves Pembrolizumab with Chemoradiotherapy for FIGO 2014 Stage III-IVA Cervical... January 25, 2024 Load more HOT NEWS EMA Recommends Extension of Indications for Nivolumab and Ipilimumab A Robust, Durable Activity of Atezolizumab Observed in a Diverse Cohort... Circulating T Cell Characteristics Associated with Immune Checkpoint Inhibitors-Induced irAEs FDA Approves Belantamab Mafodotin-blmf for Relapsed or Refractory Multiple Myeloma
